Reviewing Enovis (NYSE:ENOV) & Aspyra (OTCMKTS:APYI)

Aspyra (OTCMKTS:APYI) and Enovis (NYSE:ENOV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Valuation and Earnings

This table compares Aspyra and Enovis”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspyra	N/A	N/A	N/A	N/A	N/A
Enovis	$2.19 billion	0.79	-$825.49 million	($14.25)	-2.13

Aspyra has higher earnings, but lower revenue than Enovis.

Insider and Institutional Ownership

98.4% of Enovis shares are owned by institutional investors. 23.9% of Aspyra shares are owned by company insiders. Comparatively, 2.7% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Aspyra has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Aspyra and Enovis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspyra	0	0	0	0	0.00
Enovis	1	0	6	0	2.71

Enovis has a consensus target price of $51.00, suggesting a potential upside of 67.92%. Given Enovis’ stronger consensus rating and higher possible upside, analysts clearly believe Enovis is more favorable than Aspyra.

Profitability

This table compares Aspyra and Enovis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aspyra	N/A	N/A	N/A
Enovis	-37.80%	6.78%	3.73%

Summary

Enovis beats Aspyra on 7 of the 10 factors compared between the two stocks.

About Aspyra

Aspyra Inc. provides health care products and services for the laboratory and imaging marketplaces. It offers engineered workflow solutions that include software, interfaces, hardware, and professional services to various markets comprising specialty labs, reference labs, clinics, hospitals, imaging centers, and orthopedic practices. The company was formerly known as Creative Computer Applications Inc. and changed its name to Aspyra Inc. in November 2005. Aspyra Inc. was founded in 1978 and is headquartered in Jacksonville, Florida.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.